Loading organizations...

§ Private Profile · New York City, NY, USA
Geothermal energy company developing and installing heat pump systems for residential homeowners, replacing fossil fuel heating and cooling.
Based in Mount Kisco, New York, Dandelion Energy develops and installs residential geothermal heating and cooling systems designed to replace traditional fossil fuel infrastructure. The company manufactures proprietary heat pumps and provides direct-to-consumer retrofit installations, targeting a United States market of approximately 10 million homes currently reliant on heating oil or propane. Under the leadership of CEO Dan Yates, the enterprise is expanding its operations beyond residential retrofits to include new construction projects utilizing updated, high-efficiency heating and cooling equipment. To support this nationwide expansion, Dandelion has raised $134.5 million in total funding from a syndicate of prominent venture capital firms and corporate backers, including Breakthrough Energy Ventures, NEA, Google Ventures, and Lennar. Originally incubated within the Google X research division, the business was spun out and officially founded in 2017 by Kathy Hannun and James.
Dandelion has raised $52.5M across 4 funding rounds.
Dandelion has raised $52.5M in total across 4 funding rounds.
Dandelion has raised $52.5M across 4 funding rounds. Most recently, it raised $30.0M Series B in February 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Feb 18, 2021 | $30M Series B | Bill Gates | — | Announced |
| Feb 1, 2019 | $16M Series A | Comcast Ventures, Shaun Maguire | BAM Ventures, Canvas Ventures, Lightspeed Venture Partners, Partners Resolute, Sequoia Capital, Marco Demeireles, Thrive Capital, Collaborative Fund, Ground UP Ventures, Lennar Corporation, NEA, ZhenFund | Announced |
| Mar 27, 2018 | $4.5M Venture Round | NEW Enterprise Associates | Daniel Yates, Borealis Ventures, BoxGroup, Collaborative Fund, Ground UP Ventures, ZhenFund | Announced |
| Jul 6, 2017 | $2M Seed | Craig Shapiro | Borealis Ventures, ZhenFund | Announced |
Dandelion Health is a technology company building a Precision Medicine Platform that leverages proprietary AI tools and multimodal real-world patient data (including clinical notes, images, and waveforms) to accelerate clinical development and commercialization in life sciences.[2] It serves pharmaceutical companies, biotech firms, and researchers by providing regulatory-grade insights for stages from early research to post-approval evidence generation, solving challenges like unstructured data analysis, patient eligibility optimization, and real-world evidence for FDA submissions.[2]
Other entities named Dandelion operate in distinct areas: Dandelion Technologies develops enterprise-class software solutions[1]; Dandelion Inc. focuses on digital transformation and ad tech licensing for platforms like Google and Amazon DSP[3]; Dandelion Tech offers software development and digital innovation services[4]; and Dandelion Science creates a Generative Neuromodulation™ platform for brain disorder treatments[5]. This analysis centers on Dandelion Health as the most prominent health tech innovator matching the query's technology focus.[2]
Dandelion Health emerged to address gaps in real-world data (RWD) for clinical development, combining the richest multimodal patient records with AI to deliver deeper, regulatory-grade insights beyond traditional RWD sources.[2] Specific founding details like year, founders, or early traction are not detailed in available sources, but its platform evolved to support the full product lifecycle, from uncovering disease mechanisms in early research to generating evidence for market access and FDA approvals.[2] This positions it as a pivotal player in AI-driven precision medicine, with solutions tailored for life sciences' evolving data needs.[2]
Dandelion Health rides the AI in healthcare trend, capitalizing on explosive growth in real-world data and precision medicine amid rising demand for faster drug development and personalized treatments.[2] Timing aligns with regulatory shifts favoring RWD for approvals (e.g., FDA emphasis on real-world evidence), amplified by post-pandemic data digitization in clinical records.[2] Market forces like high clinical trial costs and protocol revisions favor its patient optimization and evidence tools, influencing the ecosystem by enabling life sciences firms to reduce timelines, enhance submissions, and model algorithm impacts across diverse populations.[2]
Dandelion Health is poised to expand its AI marketplace and platform as RWD volumes grow and regulators deepen AI/RWD integration, potentially dominating precision medicine data infrastructure.[2] Trends like multimodal AI advancements and global health data interoperability will shape its trajectory, evolving its influence toward broader therapeutic expansions and payer negotiations. As a key enabler in clinical acceleration, it ties back to its core strength: transforming raw patient data into actionable, regulatory-grade intelligence for faster innovation.[2]
Dandelion has raised $52.5M in total across 4 funding rounds.
Dandelion's investors include Bill Gates, Comcast Ventures, Shaun Maguire, Bam Ventures, Canvas Ventures, Lightspeed Venture Partners, Partners Resolute, Sequoia Capital, Marco DeMeireles, Thrive Capital, Collaborative Fund, Ground Up Ventures.